According to experts, nearly six million Americans currently have Alzheimer’s disease. Over the next seven years, that number could rise to seven million and without new therapies, more than 13 million Americans could develop this condition by the year 2050. Even as this disease continues to take a heavy toll on the US economy, researchers are concerned by the lack of doctors - both experienced and qualified - who can diagnose Alzheimer’s in its early stages, when medicines may have a greater impact.
As efforts continue to bring new Alzheimer’s treatments to the market, what role can policymakers and public health officials play in ensuring primary physicians across the country have the skills and knowledge necessary to diagnose the disease in its early stages? How can the stigma surrounding Alzheimer’s be addressed and what should be done to protect patients from discrimination?
The Hill will convene key lawmakers, health officials, industry stakeholders, researchers, physicians, patients and their advocates to continue the conversation about preparing the American health care delivery system for the possibility of a groundbreaking advancement in the treatment of Alzheimer’s.